Literature DB >> 30393068

Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer.

Craig M Bielski1, Mark T A Donoghue1, Mayur Gadiya2, Aphrothiti J Hanrahan2, Helen H Won3, Matthew T Chang4, Philip Jonsson4, Alexander V Penson4, Alexander Gorelick4, Christopher Harris1, Alison M Schram5, Aijazuddin Syed3, Ahmet Zehir3, Paul B Chapman5, David M Hyman6, David B Solit7, Kevin Shannon8, Sarat Chandarlapaty9, Michael F Berger10, Barry S Taylor11.   

Abstract

Driver mutations in oncogenes encode proteins with gain-of-function properties that enhance fitness. Heterozygous mutations are thus viewed as sufficient for tumorigenesis. We describe widespread oncogenic mutant allele imbalance in 13,448 prospectively characterized cancers. Imbalance was selected for through modest dosage increases of gain-of-fitness mutations. Negative selection targeted haplo-essential effectors of the spliceosome. Loss of the normal allele comprised a distinct class of imbalance driven by competitive fitness, which correlated with enhanced response to targeted therapies. In many cancers, an antecedent oncogenic mutation drove evolutionarily dependent allele-specific imbalance. In other instances, oncogenic mutations co-opted independent copy-number changes via the evolutionary process of exaptation. Oncogenic allele imbalance is a pervasive evolutionary innovation that enhances fitness and modulates sensitivity to targeted therapy.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cancer; competitive fitness; exaptation; oncogenes; selection; targeted therapy

Mesh:

Year:  2018        PMID: 30393068      PMCID: PMC6234065          DOI: 10.1016/j.ccell.2018.10.003

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  41 in total

1.  FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing.

Authors:  Ronglai Shen; Venkatraman E Seshan
Journal:  Nucleic Acids Res       Date:  2016-06-07       Impact factor: 16.971

2.  A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice.

Authors:  Minh D To; Jesus Perez-Losada; Jian-Hua Mao; Jeff Hsu; Tyler Jacks; Allan Balmain
Journal:  Nat Genet       Date:  2006-07-02       Impact factor: 38.330

Review 3.  The molecular genetics of cellular oncogenes.

Authors:  H E Varmus
Journal:  Annu Rev Genet       Date:  1984       Impact factor: 16.830

Review 4.  Lessons from the cancer genome.

Authors:  Levi A Garraway; Eric S Lander
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

5.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

6.  The mutational landscapes of genetic and chemical models of Kras-driven lung cancer.

Authors:  Peter M K Westcott; Kyle D Halliwill; Minh D To; Mamunur Rashid; Alistair G Rust; Thomas M Keane; Reyno Delrosario; Kuang-Yu Jen; Kay E Gurley; Christopher J Kemp; Erik Fredlund; David A Quigley; David J Adams; Allan Balmain
Journal:  Nature       Date:  2014-11-02       Impact factor: 49.962

7.  Effect of read-mapping biases on detecting allele-specific expression from RNA-sequencing data.

Authors:  Jacob F Degner; John C Marioni; Athma A Pai; Joseph K Pickrell; Everlyne Nkadori; Yoav Gilad; Jonathan K Pritchard
Journal:  Bioinformatics       Date:  2009-10-06       Impact factor: 6.937

8.  Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis.

Authors:  M D To; R D Rosario; P M K Westcott; K L Banta; A Balmain
Journal:  Oncogene       Date:  2012-09-03       Impact factor: 9.867

9.  ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.

Authors:  Weiyi Toy; Yang Shen; Helen Won; Bradley Green; Rita A Sakr; Marie Will; Zhiqiang Li; Kinisha Gala; Sean Fanning; Tari A King; Clifford Hudis; David Chen; Tetiana Taran; Gabriel Hortobagyi; Geoffrey Greene; Michael Berger; José Baselga; Sarat Chandarlapaty
Journal:  Nat Genet       Date:  2013-11-03       Impact factor: 38.330

10.  Genome doubling shapes the evolution and prognosis of advanced cancers.

Authors:  Craig M Bielski; Ahmet Zehir; Alexander V Penson; Mark T A Donoghue; Walid Chatila; Joshua Armenia; Matthew T Chang; Alison M Schram; Philip Jonsson; Chaitanya Bandlamudi; Pedram Razavi; Gopa Iyer; Mark E Robson; Zsofia K Stadler; Nikolaus Schultz; Jose Baselga; David B Solit; David M Hyman; Michael F Berger; Barry S Taylor
Journal:  Nat Genet       Date:  2018-07-16       Impact factor: 38.330

View more
  40 in total

Review 1.  Altered RNA Processing in Cancer Pathogenesis and Therapy.

Authors:  Esther A Obeng; Connor Stewart; Omar Abdel-Wahab
Journal:  Cancer Discov       Date:  2019-10-14       Impact factor: 39.397

2.  Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma.

Authors:  Yu-Hsiu T Lin; Gregory P Way; Benjamin G Barwick; Margarette C Mariano; Makeba Marcoulis; Ian D Ferguson; Christoph Driessen; Lawrence H Boise; Casey S Greene; Arun P Wiita
Journal:  Blood Adv       Date:  2019-11-12

3.  Leveraging Systematic Functional Analysis to Benchmark an In Silico Framework Distinguishes Driver from Passenger MEK Mutants in Cancer.

Authors:  Aphrothiti J Hanrahan; Brooke E Sylvester; Matthew T Chang; Arijh Elzein; Jianjiong Gao; Weiwei Han; Ye Liu; Dong Xu; Sizhi P Gao; Alexander N Gorelick; Alexis M Jones; Amber J Kiliti; Moriah H Nissan; Clare A Nimura; Abigail N Poteshman; Zhan Yao; Yijun Gao; Wenhuo Hu; Hannah C Wise; Elena I Gavrila; Alexander N Shoushtari; Shakuntala Tiwari; Agnes Viale; Omar Abdel-Wahab; Taha Merghoub; Michael F Berger; Neal Rosen; Barry S Taylor; David B Solit
Journal:  Cancer Res       Date:  2020-07-08       Impact factor: 12.701

4.  The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor.

Authors:  Kaitlyn J Andreano; Jennifer G Baker; Sunghee Park; Rachid Safi; Sandeep Artham; Steffi Oesterreich; Rinath Jeselsohn; Myles Brown; Sarah Sammons; Suzanne E Wardell; Ching-Yi Chang; John D Norris; Donald P McDonnell
Journal:  Mol Cancer Ther       Date:  2020-05-07       Impact factor: 6.261

Review 5.  Clinical cancer genomic profiling.

Authors:  Debyani Chakravarty; David B Solit
Journal:  Nat Rev Genet       Date:  2021-03-24       Impact factor: 53.242

6.  BRAF in the cross-hairs.

Authors:  Mark B Geyer; Omar Abdel-Wahab; Martin S Tallman
Journal:  Expert Rev Hematol       Date:  2019-02-26       Impact factor: 2.929

7.  Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities.

Authors:  Yosuke Tanaka; Fumiko Chiwaki; Shinya Kojima; Masahito Kawazu; Masayuki Komatsu; Toshihide Ueno; Satoshi Inoue; Shigeki Sekine; Keisuke Matsusaki; Hiromichi Matsushita; Narikazu Boku; Yae Kanai; Yasushi Yatabe; Hiroki Sasaki; Hiroyuki Mano
Journal:  Nat Cancer       Date:  2021-08-16

8.  Mutant SF3B1 promotes AKT- and NF-κB-driven mammary tumorigenesis.

Authors:  Bo Liu; Zhaoqi Liu; Sisi Chen; Michelle Ki; Caroline Erickson; Jorge S Reis-Filho; Benjamin H Durham; Qing Chang; Elisa de Stanchina; Yiwei Sun; Raul Rabadan; Omar Abdel-Wahab; Sarat Chandarlapaty
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

9.  Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression.

Authors:  Yu Mei; Wenya Linda Bi; James Agolia; Changchen Hu; Alexandra M Giantini Larsen; David M Meredith; Sally Al Abdulmohsen; Tejus Bale; Gavin P Dunn; Malak Abedalthagafi; Ian F Dunn
Journal:  Pituitary       Date:  2021-01-25       Impact factor: 4.107

Review 10.  The Role of Wild-Type RAS in Oncogenic RAS Transformation.

Authors:  Erin Sheffels; Robert L Kortum
Journal:  Genes (Basel)       Date:  2021-04-28       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.